Panel Discussion | Will DCB Play a Role for Coronary Application in the US?

Monday, March 10, 2025

10:56 AM – 11:11 AM ET

Panel Moderator(s)

Alexandre A. Abizaid, MD, PhD

Director of Invasive Cardiology
Incor
SÃO PAULO, Sao Paulo, Brazil

Disclosure(s): No financial relationships to disclose
Robert A. Byrne, MD, BCh, PhD

Director of Cardiology
Mater Private Hospital, RCSI University of Medicine and Health Sciences, Dublin, Ireland
Dublin, Ireland

Disclosure(s): No financial relationships to disclose
Florim Cuculi, MD

Head of Cardiology
Heart Center Lucerne, Luzern, Switzerland

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Bimmer Claessen, MD

Interventional cardiologist
Amsterdam University Medical Center

Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Terminated); BBraun, Philips, Infraredx, Novo Nordisk: Grant/Research Support (Ongoing); Sanofi, Philips, BBraun, Abiomed, Abbott Vascular, Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated)
Antonio Colombo, MD

Professor of Cardiology
Humanitas IRCCS
Milan, Lombardia, Italy

Disclosure(s): No financial relationships to disclose
Manish Doshi, PhD

Founder and Managing Director
Concept Medical, Florida, United States

Disclosure(s): Concept Medical: Employee (Ongoing), Stock-privately held company (Ongoing)
Jeffrey B. Jump, MSc

Chairman and CEO
MedAlliance
Nyon, Vaud, Switzerland

Disclosure(s): Transmural Systems, Inc.: Chairman (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Semih Oktay, PhD

President
Cardiomed Device Consultants
Annapolis, Maryland, United States

Disclosure(s): I am a regulatory consultant to many cardiovascular device manufacturers: Consultant (Ongoing)
Hany Ragy, MD

Director of Cath lab
hayat hospital Cairo
cairo, Egypt

Disclosure(s): No financial relationships to disclose
Patrick W. Serruys, MD, PhD

Professor of Medical Intervention & Innovation
University of Galway, Ireland

Disclosure(s): Merillife Sciences: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

Alexandre A. Abizaid, MD, PhD: No financial relationships to disclose

Robert A. Byrne, MD, BCh, PhD: No financial relationships to disclose

Florim Cuculi, MD: No financial relationships to disclose

Marianne Brodmann, MD: No financial relationships to disclose

Bimmer Claessen, MD: Amgen: Consulting Fees (e.g., advisory boards) (Terminated); BBraun, Philips, Infraredx, Novo Nordisk: Grant/Research Support (Ongoing); Sanofi, Philips, BBraun, Abiomed, Abbott Vascular, Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated)

Antonio Colombo, MD: No financial relationships to disclose

Manish Doshi, PhD: Concept Medical: Employee (Ongoing), Stock-privately held company (Ongoing)

Jeffrey B. Jump, MSc: Transmural Systems, Inc.: Chairman (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Semih Oktay, PhD: I am a regulatory consultant to many cardiovascular device manufacturers: Consultant (Ongoing)

Hany Ragy, MD: No financial relationships to disclose

Patrick W. Serruys, MD, PhD: Merillife Sciences: Consulting Fees (e.g., advisory boards) (Ongoing)

Luca Testa, MD, PhD, Professor of Cardiology: No financial relationships to disclose